Integrated Diagnostics Holdings PLC Change of Adviser (5649X)
20 Dicembre 2019 - 8:00AM
UK Regulatory
TIDMIDHC
RNS Number : 5649X
Integrated Diagnostics Holdings PLC
20 December 2019
Integrated Diagnostics Holdings Plc
20 December 2019
Appointment of Investec and Panmure Gordon as Joint Corporate
Brokers
(Cairo and London) - Integrated Diagnostics Holdings ("IDH" or
"the Company"), a leading consumer healthcare company with
operations in Egypt, Jordan, Sudan and Nigeria, is pleased to
announce the appointment of Investec Bank plc and Panmure Gordon
(UK) Limited as joint corporate brokers to the Company with
immediate effect.
-Ends-
Contacts
IDH +20 (0)2 3345 5530
Sherif El-Ghamrawi, Investor +20 (0)10 0447 8699
Relations Director sherif.elghamrawi@idhcorp.com
Investec Bank plc +44 (0)207 597 5970
Sara Hale
Daniel Adams
Duncan Wilson
Panmure Gordon +44 (0)207 886 2500
Freddy Crossley
Emma Earl
James Stearns
About Integrated Diagnostics Holdings
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg and Al Mokhtabar in Egypt, as
well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in
Sudan) and Echo-Scan (Nigeria). A long track record for quality and
safety has earned the Company a trusted reputation, as well as
internationally recognised accreditations for its portfolio of over
1,400 diagnostics tests. From its base of 424 branches as of 30
June 2019, IDH will continue to add laboratories through a Hub,
Spoke and Spike business model that provides a scalable platform
for efficient expansion. Beyond organic growth, the Group's
expansion plans include acquisitions in new Middle Eastern and
African markets where its model is well-suited to capitalise on
similar healthcare and consumer trends and capture a significant
share of fragmented markets. IDH has been a Jersey-registered
entity with a Standard Listing on the Main Market of the London
Stock Exchange (ticker: IDHC) since May 2015.
IDH's forward-looking strategy rests on leveraging its
established business model to achieve four key strategic goals,
namely: (1) continue to expand customer reach; (2) increase the
number of tests per patient; (3) expand into new geographic markets
through selective, value-accretive acquisitions; and (4) introduce
new medical services by leveraging the Group's network and
reputable brand position. Learn more at idhcorp.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPFMMMZRLZGLZM
(END) Dow Jones Newswires
December 20, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Integrated Diagnostics (LSE:IDHC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Integrated Diagnostics (LSE:IDHC)
Storico
Da Apr 2023 a Apr 2024
